Stock listing
NASDAQ:IRD Opus Genetics, Inc. Stock
Home listing (NASDAQ) of Opus Genetics, Inc.
Follow Opus Genetics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IRD
$3.99 USD +0.07 (+1.8%)
Close on Nov 20, 2026
- Day range
- $3.89 – $4.05 USDNov 20, 2026
- Volume
- 1.19M sharesNov 20, 2026
- Market cap
- $385.7M USDAt the close on Nov 20, 2026 · price × 96.65M shares outstanding
- 52-week range
- $1.86 – $7.07 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.70M USDMedian day 1.36M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IRD · Home | $3.99 USD | +0.07 (+1.8%) | 1,185,998 | $4.01 | $4.045 | $3.89 | $3.92 | Close on Nov 20, 2026 |
| Frankfurt:R3X1 | €3.58 EUR | -0.08 (-2.2%) | — | €3.72 | €3.72 | €3.50 | €3.66 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IRD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.99 | +0.07 | +1.8% | $4.01 | $4.045 | $3.89 | 1,185,998 | |
| $3.92 | -0.13 | -3.2% | $4.05 | $4.13 | $3.90 | 751,009 | |
| $4.05 | +0.01 | +0.2% | $4.02 | $4.079 | $3.915 | 729,169 | |
| $4.04 | +0.06 | +1.5% | $3.94 | $4.08 | $3.885 | 975,012 | |
| $3.98 | -0.08 | -2.0% | $4.05 | $4.17 | $3.80 | 747,347 | |
| $4.06 | -0.25 | -5.8% | $4.23 | $4.35 | $3.96 | 1,387,753 | |
| $4.31 | +0.08 | +1.9% | $4.31 | $4.52 | $4.13 | 1,206,811 | |
| $4.23 | +0.03 | +0.7% | $4.19 | $4.27 | $4.04 | 1,069,930 | |
| $4.20 | +0.02 | +0.5% | $4.24 | $4.365 | $4.154 | 1,145,651 | |
| $4.18 | +0.175 | +4.4% | $4.02 | $4.24 | $4.01 | 784,408 | |
| $4.005 | -0.265 | -6.2% | $4.26 | $4.26 | $3.795 | 1,473,772 | |
| $4.27 | +0.34 | +8.7% | $4.05 | $4.31 | $3.98 | 1,162,209 | |
| $3.93 | +0.23 | +6.2% | $3.74 | $3.99 | $3.74 | 1,129,709 | |
| $3.70 | +0.03 | +0.8% | $3.69 | $3.78 | $3.615 | 877,656 | |
| $3.67 | +0.02 | +0.5% | $3.58 | $3.69 | $3.42 | 1,019,544 | |
| $3.65 | -0.03 | -0.8% | $3.68 | $3.82 | $3.60 | 709,585 | |
| $3.68 | +0.22 | +6.4% | $3.44 | $3.69 | $3.40 | 1,033,143 | |
| $3.46 | +0.14 | +4.2% | $3.32 | $3.53 | $3.28 | 1,303,301 | |
| $3.32 | -0.15 | -4.3% | $3.49 | $3.50 | $3.23 | 1,520,145 | |
| $3.47 | -0.35 | -9.2% | $3.79 | $3.83 | $3.44 | 1,115,336 | |
| $3.82 | -0.295 | -7.2% | $4.04 | $4.10 | $3.80 | 894,736 | |
| $4.115 | +0.105 | +2.6% | $4.03 | $4.215 | $4.00 | 1,355,925 | |
| $4.01 | +0.19 | +5.0% | $3.82 | $4.145 | $3.78 | 1,461,227 | |
| $3.82 | -0.02 | -0.5% | $3.87 | $3.94 | $3.69 | 1,527,758 | |
| $3.84 | -0.21 | -5.2% | $4.12 | $4.13 | $3.75 | 2,527,000 | |
| $4.05 | -0.05 | -1.2% | $4.15 | $4.28 | $3.98 | 2,952,900 | |
| $4.10 | -0.14 | -3.3% | $4.40 | $4.40 | $4.08 | 1,198,400 | |
| $4.24 | -0.40 | -8.6% | $4.76 | $4.77 | $4.23 | 1,291,500 | |
| $4.64 | -0.01 | -0.2% | $4.63 | $4.88 | $4.60 | 1,623,200 | |
| $4.65 | +0.19 | +4.3% | $4.46 | $4.74 | $4.45 | 1,255,400 | |
| $4.46 | +0.05 | +1.1% | $4.41 | $4.48 | $4.25 | 1,345,700 | |
| $4.41 | +0.03 | +0.7% | $4.35 | $4.66 | $4.25 | 1,839,800 | |
| $4.38 | 0.00 | 0.0% | $4.47 | $4.48 | $4.19 | 2,534,000 | |
| $4.38 | -0.20 | -4.4% | $4.57 | $4.64 | $4.34 | 2,534,900 | |
| $4.58 | +0.07 | +1.6% | $4.56 | $4.67 | $4.45 | 1,789,500 | |
| $4.51 | -0.33 | -6.8% | $4.89 | $4.91 | $4.51 | 1,873,800 | |
| $4.84 | -0.12 | -2.4% | $4.96 | $5.32 | $4.83 | 2,458,000 | |
| $4.96 | -0.09 | -1.8% | $5.07 | $5.15 | $4.80 | 1,525,100 | |
| $5.05 | +0.29 | +6.1% | $4.75 | $5.14 | $4.63 | 1,161,400 | |
| $4.76 | -0.11 | -2.3% | $4.89 | $4.93 | $4.70 | 1,244,700 | |
| $4.87 | +0.04 | +0.8% | $4.76 | $4.96 | $4.60 | 1,831,200 | |
| $4.83 | -0.33 | -6.4% | $5.14 | $5.16 | $4.65 | 3,055,100 | |
| $5.16 | -0.06 | -1.1% | $5.20 | $5.30 | $5.04 | 1,172,000 | |
| $5.22 | +0.04 | +0.8% | $5.17 | $5.55 | $5.17 | 1,979,800 | |
| $5.18 | -0.10 | -1.9% | $5.29 | $5.34 | $5.11 | 5,541,000 | |
| $5.28 | -0.13 | -2.4% | $5.46 | $5.62 | $5.23 | 1,531,100 | |
| $5.41 | -0.41 | -7.0% | $5.80 | $5.80 | $5.35 | 2,335,200 | |
| $5.82 | -0.15 | -2.5% | $5.94 | $5.95 | $5.67 | 1,991,900 | |
| $5.97 | -0.07 | -1.2% | $6.02 | $6.22 | $5.80 | 2,550,100 | |
| $6.04 | -0.03 | -0.5% | $6.16 | $6.58 | $5.77 | 4,652,000 | |
| $6.07 | +0.34 | +5.9% | $5.87 | $6.24 | $5.40 | 6,536,900 | |
| $5.73 | +1.39 | +32.0% | $5.31 | $7.07 | $5.31 | 54,319,700 | |
| $4.34 | -0.33 | -7.1% | $4.53 | $4.62 | $4.31 | 2,267,600 | |
| $4.67 | +0.07 | +1.5% | $4.53 | $4.80 | $4.40 | 2,239,600 | |
| $4.60 | +0.15 | +3.4% | $4.66 | $4.83 | $4.28 | 4,425,600 | |
| $4.45 | +0.62 | +16.2% | $3.86 | $4.52 | $3.86 | 4,994,700 | |
| $3.83 | +0.21 | +5.8% | $3.65 | $3.85 | $3.59 | 868,600 | |
| $3.62 | -0.07 | -1.9% | $3.71 | $3.72 | $3.51 | 584,100 | |
| $3.69 | -0.16 | -4.2% | $3.85 | $3.86 | $3.63 | 823,600 | |
| $3.85 | +0.05 | +1.3% | $3.80 | $3.92 | $3.79 | 546,100 | |
| $3.80 | -0.31 | -7.5% | $4.17 | $4.21 | $3.77 | 908,700 | |
| $4.11 | +0.08 | +2.0% | $4.07 | $4.42 | $4.04 | 1,496,000 | |
| $4.03 | -0.02 | -0.5% | $4.02 | $4.24 | $3.82 | 812,200 | |
| $4.05 | -0.07 | -1.7% | $4.16 | $4.33 | $4.02 | 1,045,000 | |
| $4.12 | +0.05 | +1.2% | $4.01 | $4.26 | $4.01 | 1,461,500 |
Splits
3 splits since 2017 · NASDAQ:IRD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:IRD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 50 slides
Latest news
Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
Nov 19, 2026
Closed $3.99 (+1.8%) on Nov 20, 2026
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
Nov 10, 2026
Closed $4.23 (+0.7%) on Nov 10, 2026
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
Nov 5, 2026
Closed $4.01 (-6.2%) on Nov 5, 2026
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Nov 3, 2026
Closed $3.93 (+6.2%) on Nov 3, 2026
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2026
Closed $3.93 (+6.2%) on Nov 3, 2026
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Oct 29, 2026
Closed $3.65 (-0.8%) on Oct 29, 2026
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
Oct 21, 2026
Closed $4.12 (+2.6%) on Oct 21, 2026
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Oct 16, 2026
Closed $3.84 (-5.2%) on Oct 16, 2026
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Oct 15, 2026
Closed $3.84 (-5.2%) on Oct 16, 2026
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Oct 13, 2026
Closed $4.24 (-8.6%) on Oct 13, 2026
Opus Genetics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 40 in the last 12 months · 79 in all · newest Nov 19, 2026 · oldest 2021
- Decks
- 33 decks · latest November 2026
Where Opus Genetics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IRD · Home listing · This page | NASDAQ | United States | USD |
| gettex:R3X1 | gettex | Germany | EUR |
| LS Exchange:A2QG4Z | LS Exchange | Germany | EUR |
| Frankfurt:R3X1 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2QG4Z | Lang & Schwarz | Germany | EUR |
| BOATS:IRD | BOATS | United States | USD |
| Tradegate:R3X1 | Tradegate | Germany | EUR |
| Dusseldorf:R3X1 | Dusseldorf | Germany | EUR |
| Munich:R3X1 | Munich | Germany | EUR |
| Stuttgart:R3X1 | Stuttgart | Germany | EUR |
Valuation
EV/sales 42.0× against a median of 23.0×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $332.3M USD
- P/E
- Loss
- EV/sales
- 42.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.0×
- Gross margin
- 99.8%
- Operating margin
- −777.7%
- Net margin
- Revenue too small
- Debt to equity
- 0.9×
- Beta vs S&P 500
- 1.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Opus Genetics, Inc. · NASDAQ:IRD | US$385.7M | US$332.3M | n/a | 42.0× | n/a | 10.0× | n/a | 0.9× | 1.01 |
| Ever Supreme Bio Technology Co., Ltd. · TPEX:6712 | US$394.8M | US$362.8M | 27.5× | 11.1× | 23.9× | 4.6× | 43.8% | 0.0× | n/a |
| Mezzion Pharma Co., Ltd. · KRX:140410 | US$391.0M | US$360.8M | n/a | 57.3× | n/a | 13.4× | −325.0% | 0.0× | n/a |
| Avalo Therapeutics, Inc. · NASDAQ:AVTX | US$390.9M | −US$1.93M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.25 |
| Qurient Co., Ltd. · KRX:115180 | US$388.5M | US$372.4M | n/a | 70.5× | n/a | 30.2× | −543.0% | 0.8× | n/a |
| Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480 | US$388.2M | US$369.1M | n/a | n/a | n/a | 4.3× | n/a | 0.4× | n/a |
| Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378 | US$387.5M | US$316.0M | n/a | n/a | n/a | 4.1× | n/a | 0.1× | n/a |
| Eupraxia Pharmaceuticals, Inc. · TSX:EPRX | US$384.3M | US$252.7M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.53 |
| Hinova Pharmaceuticals, Inc. Class A · SSE:688302 | US$381.1M | US$285.9M | n/a | 23.0× | n/a | 2.6× | −167.3% | 0.1× | n/a |
| Rezolute, Inc. · NASDAQ:RZLT | US$379.2M | US$289.9M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.28 |
| Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT | US$378.8M | US$359.8M | n/a | 1.3× | n/a | n/a | −30.2% | n/a | 1.08 |
| Median of the others | US$387.9M | US$337.9M | 27.5× | 23.0× | 23.9× | 4.3× | −167.3% | 0.0× | 1.27 |
Forecasts
15 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 13.59 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.24 · 4 analysts
- Revenue, year to Dec 2026
- 14.14M · 17 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| George Magrath | Chief Executive Officer |
| Robert Gagnon | Chief Financial Officer |
| Joe Schachle | Chief Operating Officer |
| Andrew Murphy | Chief Scientific Officer |
| Ben Yerxa | |
| Chris Ernst | Chief Technology Officer |
| Sally Tucker | Chief Medical Officer |
| Sarah Tuller | Chief Regulatory Officer |
Board
| Director | Role |
|---|---|
| Cam Gallagher | Chairman of the Board |
| Adrienne Graves | |
| Ben Yerxa | |
| Richard Rodgers | Director |
| Susan Benton |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +0.7% |
| Q2 2026 | Aug 6, 2026 · Before open | −1.6% |
| Q1 2026 | May 12, 2026 · Before open | +1.2% |
| Q4 2025 | Feb 25, 2026 | −1.4% |
| Q3 2025 | Nov 12, 2025 · Before open | −2.5% |
| Q2 2025 | Aug 13, 2025 · After close | +7.3% |
| Q1 2025 | May 15, 2025 · Before open | 0.0% |
| Q4 2024 | Mar 31, 2025 | −9.9% |
| Q3 2024 | Nov 12, 2024 · Before open | −2.6% |
| Q2 2024 | Aug 13, 2024 · Before open | −21.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | −2.3% |
| Q4 2023 | Mar 8, 2024 | −12.2% |
| Q3 2023 | Nov 13, 2023 · Before open | +1.8% |
| Q2 2023 | Aug 11, 2023 · Before open | +1.9% |
| Q1 2023 | May 15, 2023 | −18.9% |
| Q4 2022 | Mar 30, 2023 · After close | −2.1% |
| Q3 2022 | Nov 4, 2022 · After close | −5.0% |
| Q2 2022 | Aug 12, 2022 · Before open | −9.0% |
| Q1 2022 | May 13, 2022 · Before open | +8.0% |
| Q4 2021 | Mar 24, 2022 | +11.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 50 slides | November 2026 |
| Retina in Rio 2026 | Conference | 25 slides | Oct 15, 2026 |
| Corporate Update (October 2026) | Corporate update | 12 slides | Oct 15, 2026 |
| Investor Presentation (October 2026) | Investor deck | 50 slides | October 2026 |
| Euretina 2026 | Conference | 11 slides | October 2026 |
| Retina Forum 2026 | Conference | 15 slides | Sep 30, 2026 |
| Technical Presentation (September 2026) | Technical | 36 slides | Sep 9, 2026 |
| Technical Presentation (September 2026) | Technical | 39 slides | Sep 9, 2026 |
| Technical Presentation (June 2026) | Technical | 80 slides | Jun 16, 2026 |
| Technical Presentation (May 2026) | Technical | 24 slides | May 13, 2026 |
All 33 decks
Financings
| Raise | Date |
|---|---|
| Private placement of series B Non-Voting Convertible Preferred Stock Announced: US$25M · US$3.39 a share Buyers: Adage Capital Management; Trails Edge Capital Partners; Marshall Wace Use of proceeds: Advance gene therapy clinical programs, working capital and general corporate purposes | Feb 13, 2026 |
| Registered direct offering of equity securities Closed: US$23M raised · US$2.09 a share Buyers: Perceptive Advisors (led the financing); Balyasny Asset Management (led the financing); Nantahala Capital (participated) Use of proceeds: Advance LCA5 and BEST-1 gene therapy clinical programs, working capital and general corporate purposes | Nov 12, 2025 |
| Public offering of shares of common stock, or common stock equivalents, and warrants Closed: US$20M raised · US$0.95 a share · Warrants at US$0.95 for 60 months · Craig-Hallum Dealers: Craig-Hallum (lead) Buyers: Perceptive Advisors; Nantahala Capital Use of proceeds: Extending cash runway and funding key upcoming milestones for the gene therapy portfolio | Mar 31, 2025 |
| Private placement of shares of common stock and warrants Closed: US$1.5M raised · US$1.275 a share · Warrants at US$1.15 for 60 months Buyers: George Magrath; Cam Gallagher Insiders: CEO George Magrath and board chairman Cam Gallagher participated Use of proceeds: Clinical development of OPGx-LCA5 and OPGx-BEST1 gene therapy programs, general corporate purposes and working capital | Mar 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.2M | 11.0M | 19.0M | 39.9M | 589.0K | 0 | 3.00M | |||
| Cost of revenue | 53.0K | 10.0K | 6.00K | 4.00K | 4.00K | 8.00K | ||||
| Gross profit | 14.2M | 11.0M | 19.0M | 39.9M | 589.0K | -8.00K | ||||
| Research and development | 30.8M | 26.9M | 17.7M | 14.4M | 15.2M | 6.65M | 5.48M | 13.1M | 10.7M | 10.1M |
| Selling, general and administrative | 22.0M | 18.2M | 12.0M | 7.27M | 8.12M | 2.82M | 1.82M | |||
| Operating income | -38.6M | -62.1M | -10.6M | 18.2M | -22.7M | -20.0M | -4.19M | -20.5M | -17.4M | -16.4M |
| Depreciation and amortization | 53.0K | 10.0K | 6.00K | 4.00K | 4.00K | 8.00K | 41.0K | 48.2K | 42.4K | 32.9K |
| EBITDA | -38.5M | -62.1M | -10.6M | 18.2M | -22.7M | -20.0M | -4.15M | -20.5M | -17.3M | -16.4M |
| Interest expense | 129.0K | 0 | 0 | 9.00K | 2.00K | 6.85M | 1.41M | |||
| Income before tax | -49.6M | -57.5M | -9.97M | 18.2M | -56.7M | -24.6M | -6.17M | -14.4M | -25.3M | -9.31M |
| Income tax | 0 | 0 | 12.0K | 315.0K | 0 | 0 | 0 | |||
| Net income | -49.6M | -57.5M | -9.99M | 17.9M | -56.7M | -24.6M | -6.17M | -14.4M | -25.3M | -9.31M |
| Earnings per share, basic | -0.80 | -2.15 | -0.46 | 0.90 | -3.82 | -5.28 | -2.17 | -5.25 | -0.92 | -0.43 |
| Earnings per share, diluted | -0.80 | -2.15 | -0.46 | 0.87 | -3.82 | -5.28 | -2.17 | -5.25 | -0.92 | -0.43 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 45.1M | 30.3M | 50.5M | 42.6M | 24.5M | 16.4M | 1.54M | 8.74M | 8.90M | 11.6M |
| Short-term investments | 0 | 2.00K | 15.0K | 49.0K | 219.0K | 0 | ||||
| Receivables | 2.00M | 3.56M | 926.0K | 1.30M | 0 | 0 | 125.0K | |||
| Current assets | 50.0M | 36.6M | 53.9M | 49.0M | 26.1M | 17.7M | 1.76M | 15.9M | 28.1M | 20.9M |
| Property, plant and equipment | 199.0K | 252.0K | 0 | 6.00K | 10.0K | 14.0K | 22.0K | 112.5K | 121.5K | 88.7K |
| Total assets | 50.2M | 36.9M | 53.9M | 49.0M | 26.1M | 17.7M | 1.78M | 16.0M | 28.3M | 21.0M |
| Accounts payable | 3.29M | 3.15M | 2.15M | 1.07M | 1.58M | 1.21M | 342.0K | |||
| Current liabilities | 7.78M | 11.3M | 4.04M | 2.75M | 3.85M | 3.19M | 9.34M | 3.15M | ||
| Long-term debt | 1.13M | 0 | ||||||||
| Total debt | 1.13M | 0 | 538.0K | 5.67M | ||||||
| Total liabilities | 34.9M | 11.3M | 4.04M | 2.75M | 3.85M | 31.1M | 9.34M | 5.48M | 11.5M | 3.99M |
| Shareholders' equity | 15.3M | 6.72M | 49.9M | 46.2M | 22.2M | -13.5M | -7.56M | -1.70M | 16.8M | 17.1M |
| Shares outstanding | 69.9M | 31.6M | 24.0M | 20.9M | 18.8M | 10.9M | 2.85M | 3.12M | 31.7M | 23.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -35.3M | -25.6M | -1.11M | 14.3M | -19.4M | -6.80M | -3.59M | -18.8M | -15.4M | -13.2M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | -25.0K | |||
| Free cash flow | -35.3M | -25.6M | -1.11M | 14.3M | -19.4M | -6.80M | -3.62M | |||
| Cash from investing | 0 | 1.21M | 0 | 0 | -100.0K | 539.0K | -25.0K | 11.9M | -9.37M | 4.48M |
| Cash from financing | 50.0M | 4.19M | 8.98M | 3.79M | 27.6M | 21.1M | 4.70M | 6.77M | 22.1M | 10.1M |
| Share buybacks | -152.0K | -79.0K | 0 | |||||||
| Change in cash | 14.8M | -20.2M | 7.87M | 18.1M | 8.13M | 14.9M | 1.09M | -154.9K | -2.68M | 1.38M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 23, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 21, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 424B2 · Prospectus | Jun 17, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 11, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 5, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 14, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2026 | Financing | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 22, 2026 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 20, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 7, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 6, 2026 | Material contract | SEC |
| ARS · Annual report to shareholders | Mar 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 13, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Mar 12, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 22, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Nov 6, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 4/A · Change in ownership, amended | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 26, 2025 | Offer document | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 11, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 10, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 2, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Financing | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 26, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 20, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 1, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2025 | Meeting notice | SEC |
| PX14A6G | Apr 11, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DFAN14A | Apr 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 8, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 7, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 4, 2025 | Offer document | SEC |
| PRRN14A | Apr 4, 2025 | Other filings | SEC |
| DEFC14A | Apr 2, 2025 | Other filings | SEC |
| DFAN14A | Apr 2, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 31, 2025 | Big-stake notice | SEC |
| PRER14A | Mar 31, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Mar 28, 2025 | Other filings | SEC |
| DFAN14A | Mar 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 24, 2025 | Financing | SEC |
| 424B5 · Prospectus | Mar 24, 2025 | Offer document | SEC |
| DFAN14A | Mar 21, 2025 | Other filings | SEC |
| PRER14A | Mar 21, 2025 | Other filings | SEC |
| PREC14A | Mar 21, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Mar 21, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| FWP · Free writing prospectus | Mar 20, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Mar 20, 2025 | Offer document | SEC |
| PREC14A | Mar 20, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Opus Genetics, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 96,654,336
- Fully diluted
- 96,654,336
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 96,654,336 | Nov 6, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.95 · expire about Mar 2030 |
| Warrants · US$1.15 · expire about Mar 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 96,654,336 |
| Sep 30, 2026 | 95,799,574 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adrienne L. Graves Other companies: Harrow, Inc. (Member, Board of Directors, Independent Director · Since at least Jan 26, 2024); Ocular Therapeutix, Inc. (Director · Since at least Jul 10, 2023); IVERIC bio Inc (Director · Dec 12, 2018 – Jul 11, 2023 · Past); Akorn Inc (Director · Jul 1, 2016 – May 9, 2019 · Past); TearLab Corporation (TEAR) (Director · Jun 24, 2016 – Jun 24, 2016 · Past) | Director · Since at least Oct 22, 2024 |
| James S. Manuso Other companies: TuHURA Biosciences, Inc. (Chairman of the Board of Directors · Since at least Oct 18, 2024); RespireRx Pharmaceuticals Inc (President and CEO, Director · Feb 4, 2016 – Sep 13, 2017 · Past); Astex Pharmaceuticals Inc (Chief Executive Officer, Director · Mar 15, 2010 – Oct 11, 2013 · Past) | Director · Since at least Nov 5, 2020 |
| Cam Gallagher Other companies: Zentalis Pharmaceuticals, Inc. (President, Interim CFO, Director · Feb 1, 2024 – May 31, 2024 · Past) | Director · Since at least Jun 11, 2024 |
| Nirav Jhaveri Other companies: Longeveron Inc. (Chief Financial Officer · Since at least Aug 17, 2026) | Chief Financial Officer · Feb 12, 2024 – Mar 13, 2025 · Past |
| Alan R Meyer | Director · Nov 5, 2020 – Nov 19, 2020 · Past |
| Andrew Murphy | Chief Scientific Officer · Since at least Oct 29, 2026 |
| Ashwath Jayagopal | Chief Scientific & Dev. Ofc. · Since at least Feb 12, 2024 |
| Ben Yerxa | President, Director · Since at least Apr 23, 2026 |
| Charles Beever | Director · Jun 6, 2019 – Jun 6, 2019 · Past |
| Chris Ernst | Chief Technology Officer · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| George Magrath | Chief Executive Officer · Since at least Nov 1, 2023 |
| Jay Pepose | Director · Apr 8, 2022 – Jun 11, 2024 · Past |
| Joe Schachle | Chief Operating Officer · Since at least Jan 22, 2026 |
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance · Since at least Nov 11, 2020 |
| Richard Rodgers | Director · Since at least Apr 22, 2026 |
| Robert Gagnon | Chief Financial Officer · Since at least Sep 2, 2025 |
| Ronil A Patel | Chief Business Officer · Apr 24, 2023 – Jan 10, 2024 · Past |
| Sally Tucker | Chief Medical Officer · Since at least Nov 5, 2026 |
| Sarah Tuller | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Sean Ainsworth | Director · Since at least Apr 30, 2025 |
| Susan Benton | Director · Since at least Nov 5, 2020 |
Log in to ask 6ix AI your own questions about Opus Genetics, Inc.